Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study tested an experimental drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or stopped responding to other treatments. The goal was to see if the drug could shrink or eliminate tumors. Participants received the drug by infusion, and resea…

This early-stage study tested a new drug called KL340399 in 6 people with advanced solid tumors that had not responded to standard treatments. The drug was injected directly into the tumor to see if it was safe and what dose might work best. The main goal was to find the highest …

This early-phase study tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it could shrink tumors. The study was completed, but…

This study tested an experimental drug called KL-A167 in 153 adults with recurrent or metastatic nasopharyngeal carcinoma (a type of nose and throat cancer) that had already been treated with chemotherapy. The main goal was to see if the drug could shrink tumors. The study is com…

This study tested whether a new drug called A140 works as well as the standard drug Erbitux for people with a certain type of advanced colorectal cancer (RAS wild-type). Both drugs were given together with chemotherapy. The trial involved 688 adults and measured how many patients…

This early-stage study tested a new antibody drug (anti-EGFr) in 18 people with advanced colorectal cancer that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received the drug weekly until their d…